Pediatric Nephrology

, Volume 28, Issue 4, pp 577-582

First online:

Beyond mineral metabolism, is there an interplay between FGF23 and vitamin D in innate immunity?

  • Justine BacchettaAffiliated withCentre de Référence des Maladies Rénales Rares, Hôpital Femme Mère Enfant, Hospices Civils de LyonUniversité de LyonInstitut de Génomique Fonctionnelle de Lyon (IGFL), Ecole Normale SupérieureCentre de Référence des Maladies Rénales Rares, Service de Néphrologie et Rhumatologie Pédiatriques, Hôpital Femme Mère Enfant Email author 
  • , Isidro B. SaluskyAffiliated withDepartment of Pediatrics, David Geffen School of Medicine, University of California at Los Angeles
  • , Martin HewisonAffiliated withOrthopaedic Research Hospital, University of California at Los Angeles

Rent the article at a discount

Rent now

* Final gross prices may vary according to local VAT.

Get Access


Fibroblast growth factor 23 (FGF23) is an “endocrine” FGF acting in the kidney as a phosphaturic hormone and a suppressor of active vitamin D, through an inhibition of the 1α hydroxylase and a stimulation of the 24 hydroxylase. Beyond its well-known effects on the bone/kidney/parathyroid axis and its deregulation during chronic kidney disease (CKD), recent evidence has revealed its direct systemic effects on cardiovascular health. In the meantime, studies have highlighted the health implications for vitamin D inside and outside CKD that also extend beyond its classical actions on mineral homeostasis and bone metabolism: vitamin D has indeed been shown to exert pluripotent non-classical effects as a modulator of immune function in monocytes, mainly through the stimulation of the antimicrobial cathelicidin. The aim of this review is to provide new insights on the interplay between FGF23 and vitamin D in innate immunity in the context of CKD.


Children CKD FGF23 Immunity